8-K: Palisade Bio Announces Positive Preclinical Data for PALI-2108 at Crohn's & Colitis Congress

Palisade Bio announced positive preclinical data for its lead asset, PALI-2108, a novel oral PDE4 inhibitor prodrug for ulcerative colitis, at the 2024 Crohn's & Colitis Congress.

Summary

• Palisade Bio presented positive preclinical data for PALI-2108, an orally administered, colon-specific PDE4B inhibitor prodrug, at the Crohn's & Colitis Congress.
• PALI-2108 is being developed for the treatment of moderate-to-severe ulcerative colitis (UC).
• Preclinical studies showed PALI-2108 to be safe and well-tolerated, with local bioactivation and low systemic exposure.
• The drug demonstrated a significant reduction in disease activity index (DAI) score in a mouse model of UC.
• PALI-2108's design allows for minimal absorption until cleaved by a colonic enzyme, ensuring localized distribution.
• The colon/plasma AUC ratio exceeded 200, highlighting the drug's preference for the colon.
• A tolerated dose study in dogs revealed no CNS toxicity or emesis at effective doses.
• The company is advancing PALI-2108 towards a Phase 1 clinical study, expected to commence in 2024.
• Current therapies for inflammatory bowel disease (IBD) achieve a clinical remission rate of less than 20% on average.

Sentiment

Score: 8

Explanation: The document presents positive preclinical data and a clear path forward for PALI-2108, indicating a strong positive sentiment. The focus on addressing limitations of current therapies and the potential for a new treatment approach are also positive.

Positives

• PALI-2108 is orally delivered and colon-activated, allowing for local activity with low systemic exposure.
• Preclinical data showed PALI-2108 to be safe and well-tolerated.
• The drug demonstrated a significant reduction in disease activity in a mouse model of UC.
• PALI-2108 has a large therapeutic window due to local activation.
• The company is progressing towards a Phase 1 clinical study.

Risks

• The company's ability to advance its clinical programs is subject to risks and uncertainties.
• The regulatory approval process is uncertain and time-consuming.
• The company's ability to secure additional financing to fund future operations is a risk.
• The company faces competition from other technologies in the market.
• The company's ability to maintain its Nasdaq listing is a risk.

Future Outlook

The company is working diligently to launch a Phase 1 study of PALI-2108 later this year and is eager to continue to gain experience on the potential of this therapy.

Management Comments

• Mitchell Jones, M.D., Ph.D., Chief Medical Officer of Palisade Bio, commented, 'PALI-2108 continues to demonstrate promise as a novel therapy for UC, with colon-selective bioactivation, an expanded therapeutic window, reduced CNS toxicity, potent PDE4 inhibitory activity, and impressive efficacy in preclinical models.'
• Dr. Jones also stated, 'We are pleased with our growing body of evidence, including support for a precision medicine approach and the selection of potential responders, which validate the continued development of this program.'
• Dr. Jones added, 'We believe this innovative approach has the potential to revolutionize UC treatment and enhance patient outcomes.'

Industry Context

The announcement highlights the ongoing efforts to develop more effective treatments for ulcerative colitis, a significant unmet medical need. The focus on localized drug delivery and reduced systemic toxicity aligns with current trends in drug development for inflammatory bowel diseases.

Comparison to Industry Standards

• Current therapies for IBD achieve a clinical remission rate of less than 20% on average, highlighting the need for new approaches like PALI-2108.
• The development of PALI-2108 addresses the limitations of current PDE4 inhibitors, such as CNS toxicity and systemic distribution, which often lead to therapy discontinuation.
• The colon-specific delivery of PALI-2108 is a novel approach compared to traditional oral medications that have systemic effects.
• The preclinical results of PALI-2108, including the colon/plasma AUC ratio exceeding 200, suggest a significant improvement in targeted drug delivery compared to existing treatments.

Stakeholder Impact

• Shareholders may view the positive preclinical data as a positive development for the company.
• Patients with ulcerative colitis may benefit from the development of a new and potentially more effective treatment.
• Employees may be motivated by the progress of the company's lead asset.

Next Steps

• The company plans to launch a Phase 1 clinical study of PALI-2108 later this year.

Key Dates

Keywords

PALI-2108, Ulcerative Colitis, PDE4 Inhibitor, Preclinical Data, Crohn's & Colitis Congress, Gastrointestinal Diseases, Inflammatory Bowel Disease, Clinical Study, Bioactivation, Colon-Specific